DNLI insider sale: 2,937 common shares via Morgan Stanley

Rhea-AI Filing Summary

Denali Therapeutics reported a proposed sale of 2,937 common shares acquired on 08/11/2025 through a restricted stock lapse as equity compensation. The filing lists the aggregate market value as $39,876.18 and shows 146,419,263 shares outstanding. The sale is planned to occur approximately on 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filer reports "Nothing to Report" for securities sold in the past three months and includes the standard attestation that they do not possess undisclosed material adverse information.

Positive

• Full disclosure of acquisition method: restricted stock lapse and classification as equity compensation.
• No securities sold by the filer in the past three months ("Nothing to Report"), showing recent restraint.

Negative

• None.

Insights

Securities Analyst

TL;DR: Small planned sale of 2,937 shares from restricted stock lapse; limited market impact.

The Form 144 discloses a proposed sale of 2,937 common shares with an aggregate market value of $39,876.18, to be executed on NASDAQ via Morgan Stanley. The shares were acquired on 08/11/2025 through a restricted stock lapse and are identified as equity compensation. The filer reports no other sales in the past three months. Given the size and the compensation origin, this appears to be a routine insider monetization rather than a material dilution event.

Corporate Governance Expert

TL;DR: Filing documents standard insider sale and includes required attestation about material nonpublic information.

The notice includes the customary representation that the person signing does not know material adverse undisclosed information and references the Rule 10b5-1 trading plan language. The transaction is recorded as arising from a restricted stock lapse and classified as equity compensation, and the filing states "Nothing to Report" for prior three-month sales. From a governance perspective, the form meets disclosure requirements for an insider sale of compensation shares.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Fl. New York NY 10004	2937	39876.18	146419263	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2025	Restricted Stock Lapse - See Remarks	Denali Therapeutics Inc.			2937	08/11/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did DNLI file on Form 144?

DNLI filed a Form 144 disclosing a proposed sale of 2,937 common shares acquired via a restricted stock lapse, aggregate value $39,876.18.

When were the shares acquired and when is the sale planned?

The shares were acquired on 08/11/2025 and the approximate date of sale is 08/12/2025.

Through which broker will DNLI shares be sold?

The filing names Morgan Stanley Smith Barney LLC as the broker for the proposed sale.

Are these shares from compensation or purchase?

The securities were acquired by a restricted stock lapse and paid as equity compensation.

Did the filer report any securities sold in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.